Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert Maslansky is active.

Publication


Featured researches published by Robert Maslansky.


Journal of Substance Abuse Treatment | 1992

Crack cocaine use in a cohort of methadone maintenance patients

C Des Jarlais Don; John Wenston; Samuel R. Friedman; Jo L. Sotheran; Robert Maslansky; Michael Marmor

We examined crack use in a cohort of methadone patients originally enrolled in 1984-86. Crack use questions were added to the study in 1987. Of the 494 methadone patients originally enrolled, 228 subjects remained in methadone and were re-interviewed in 1987-88, and 234 remained in methadone and were re-interviewed in 1988-89. Approximately one-quarter of the subjects were using crack at each of the 1987-88 and 1988-89 data collection points, and only 3% of the subjects were using crack at daily or greater frequencies at each of the 1987-88 and 1988-89 interviews. Concurrent crack use was associated with (a) the number of noninjected drugs being used; (b) the number of IV drug-using sexual partners; (c) drug injection; and (d) the use of nonheroin opiates. Persistent crack use, defined as use in both 1987-88 and 1988-89, was associated with previous noninjected drug use and previous suicide attempts. While the potential problem of crack use among methadone patients should not be minimized, it appears that, compared to illicit drug injectors not in treatment, being in methadone maintenance may offer a protective effect against crack use.


American Journal of Public Health | 1995

Tuberculosis knowledge among New York City injection drug users.

Hannah Wolfe; Michael F. Marmor; Robert Maslansky; Stuart Nichols; M. Simberkoff; Don C. Des Jarlais; Andrew R. Moss

Structured interviews measuring tuberculosis knowledge were administered to 494 New York City injection drug users, 31% of whom reported a history of having a reactive tuberculin skin test. Medical records review of a subsample confirmed the validity of self-reported data. Most respondents understood the mechanisms of tuberculosis transmission. Three fourths of the subjects did not fully understand the distinction between a reactive skin test and active tuberculosis, but those who reported a history of skin test reactivity were twice as likely to understand this distinction. Forty percent of subjects did not understand the importance of medication adherence. Misunderstandings, based on a recent lack of tuberculosis education, may contribute to the fear and confusion that interfere with efforts to control tuberculosis.


American Journal of Drug and Alcohol Abuse | 1990

Treatment retention of patients referred by public assistance to an alcoholism clinic

David Brizer; Robert Maslansky; Marc Galanter

In order to ascertain the relative impact of coercion by a welfare program on retention in an ambulatory alcoholism program, records of 178 consecutive admissions to an inner-city alcoholism clinic were reviewed. Patients who came to the clinic via coerced referral from a public assistance agency were as likely to remain in treatment for at least nine sessions as self-referred patients.


Journal of Addictive Diseases | 2003

Short-term buprenorphine maintenance: treatment outcome.

Marc Galanter; Helen Dermatis; Richard B. Resnick; Robert Maslansky; Erna Neumann

Abstract Fifty-two heroin addicts were inducted onto buprenorphine under the care of psychiatric residents in a setting modeled on office practice. Subjects were maintained on a protocol of six weeks of 16 mg daily dosing, then tapered to zero dose up to week 16, and maintained on placebo through week 18. Of 44 subjects who continued after the first induction dose, 11 terminated during maintenance, 17 during taper; and 16 while on zero dose. Twice weekly urine toxicologies showed significant successive declines in samples positive for heroin use across these three periods: 70%, 41%, and 20%, respectively. Among historical variables, only prior AA attendance distinguished subjects who achieved zero dose from those who did not. A comparison with recent studies suggests that relatively inexperienced office-based physicians can maintain patients on buprenorphine at a level comparable to that reported for research clinic settings, but with comparable rates of heroin abstinence. These findings are discussed in light of potential options for office-based opioid maintenance.


American Journal of Public Health | 1992

Implications of the revised surveillance definition: AIDS among New York City drug users.

Don C. Des Jarlais; John Wenston; S. R. Friedman; Jo L. Sotheran; Robert Maslansky; Michael F. Marmor; Stanley Yancovitz; Sara T. Beatrice

The Centers for Disease Control (CDC) has proposed revising the AIDS surveillance definition to include any HIV-seropositive person with a CD4 cell count of less than 200 cells per microliter. Based on a study of persons receiving treatment for HIV infection, this new definition would lead to an estimated 50% increase in the number of persons recognized as living with AIDS. Among 440 HIV-seropositive research subjects recruited from drug treatment programs and through street outreach in New York City, 59 met this definition, yet only 25% of those had been reported to the New York City AIDS registry. The new definition, if combined with HIV and T-cell testing at drug treatment and street outreach programs, could thus yield very large increases in the number of injecting drug users meeting the new surveillance definition of AIDS.


International Journal of Gynecology & Obstetrics | 1989

HIV‐1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987

Don C. Des Jarlais; S. R. Friedman; David M. Novick; Jo L. Sotheran; Pauline Thomas; Stanley Yancovitz; Donna Mildvan; John M. Weber; Mary Jeanne Kreek; Robert Maslansky; S Bartelme; Thomas J. Spira; Michael F. Marmor

Intravenous drug users are the second largest group to develop the acquired immunodeficiency syndrome, and they are the primary source for heterosexual and perinatal transmission in the United States and Europe. Understanding long-term trends in the spread of human immunodeficiency virus among intravenous drug users is critical to controlling the acquired immunodeficiency syndrome epidemic. Acquired immunodeficiency syndrome surveillance data and seroprevalence studies of drug treatment program entrants are used to trace seroprevalence trends among intravenous drug users in the borough of Manhattan. The virus entered this drug-using group during the mid-1970s and spread rapidly in 1979 through 1983. From 1984 through 1987, the seroprevalence rate stabilized between 55% and 60%--well below hepatitis B seroprevalence rates. This relatively constant rate is attributed to new infections, new seronegative persons beginning drug injection, seropositive persons leaving drug injection, and increasing conscious risk reduction.


JAMA | 1989

HIV-1 Infection Among Intravenous Drug Users in Manhattan, New York City, From 1977 Through 1987

Don C. Des Jarlais; Samuel R. Friedman; David M. Novick; Jo L. Sotheran; Pauline A. Thomas; Stanley R. Yancovitz; Donna Mildvan; John M. Weber; Mary Jeanne Kreek; Robert Maslansky; Sarah Bartelme; Thomas J. Spira; Michael F. Marmor


American Journal of Cardiology | 2004

Coronary artery disease and opioid use

Michael Marmor; Arthur Penn; Kyle Widmer; Richard I. Levin; Robert Maslansky


Journal of Substance Abuse Treatment | 2004

Network therapy: decreased secondary opioid use during buprenorphine maintenance.

Marc Galanter; Helen Dermatis; Linda Glickman; Robert Maslansky; M.Brealyn Sellers; Erna Neumann; Claudia Rahman-Dujarric


AIDS Research and Human Retroviruses | 1994

Preparations for AIDS vaccine trials. Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs.

Michael F. Marmor; Stephen P. Titus; Hannah Wolfe; Keith Krasinski; Robert Maslansky; M. Simberkoff; Sara T. Beatrice; Stuart Nichols; D. C. Des Jarlais

Collaboration


Dive into the Robert Maslansky's collaboration.

Top Co-Authors

Avatar

Marc Galanter

Nathan Kline Institute for Psychiatric Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Don C. Des Jarlais

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jo L. Sotheran

National Development and Research Institutes

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David M. Novick

City University of New York

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Helen Dermatis

NewYork–Presbyterian Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge